<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Treatment options for patients with recurrent <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> refractory to pharmacotherapy and ablation are minimal </plain></SENT>
<SENT sid="1" pm="."><plain>Although left cardiac sympathetic denervation (LCSD) is well established in <z:hpo ids='HP_0001657'>long-QT syndrome</z:hpo>, its role in non-<z:hpo ids='HP_0001657'>long-QT syndrome</z:hpo> arrhythmogenic <z:e sem="disease" ids="C1720983" disease_type="Disease or Syndrome" abbrv="">channelopathies</z:e> and <z:hpo ids='HP_0001638'>cardiomyopathies</z:hpo> is less clear </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we report our single-center experience in performing LCSD in this setting </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS AND RESULTS: In this institutional review board-approved study, we retrospectively reviewed the electronic medical records of <z:hpo ids='HP_0000001'>all</z:hpo> patients (N=91) who had videoscopic LCSD at our institution from 2005 to 2011 </plain></SENT>
<SENT sid="4" pm="."><plain>Data were analyzed for the subset (n=27) who were denervated for an underlying diagnosis other than <z:hpo ids='HP_0000006'>autosomal dominant</z:hpo> or <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:hpo ids='HP_0001657'>long-QT syndrome</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>The spectrum of arrhythmogenic disease included catecholaminergic polymorphic <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> (n=13), <z:e sem="disease" ids="C0022387" disease_type="Disease or Syndrome" abbrv="">Jervell and Lange-Nielsen syndrome</z:e> (n=5), idiopathic <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> (n=4), left ventricular noncompaction (n=2), <z:hpo ids='HP_0001639'>hypertrophic cardiomyopathy</z:hpo> (n=1), ischemic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> (n=1), and <z:hpo ids='HP_0011663'>arrhythmogenic right ventricular cardiomyopathy</z:hpo> (n=1) </plain></SENT>
<SENT sid="6" pm="."><plain>Five patients had LCSD because of high-risk assessment and β-blocker intolerance, none of whom had a sentinel breakthrough cardiac event at early follow-up </plain></SENT>
<SENT sid="7" pm="."><plain>Among the remaining 22 previously symptomatic patients who had LCSD as secondary prevention, <z:hpo ids='HP_0000001'>all</z:hpo> had an attenuation in cardiac events, with 18 having no breakthrough cardiac events so far and 4 having experienced ≥1 post-LCSD breakthrough cardiac event </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: LCSD may represent a substrate-independent antifibrillatory treatment option for patients with life-threatening <z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo> <z:e sem="disease" ids="C1558937" disease_type="Disease or Syndrome" abbrv="">syndromes other</z:e> than <z:hpo ids='HP_0001657'>long-QT syndrome</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>The early follow-up seems promising, with a marked reduction in the frequency of cardiac events postdenervation </plain></SENT>
</text></document>